Abstracts tagged "Etanercept and pediatrics"

Abstract Number: 2276 • ACR/ARHP Annual Meeting 2017
Etanercept (Enbrel®) Treatment Retention in the Sub-Population of Pediatric Patients from a Retrospective Cohort Study Using Canadian Claims-Level Data
Majed M M Khraishi¹, Brad Millson², John Woolcott³, Heather Jones⁴ and Lisa Marshall⁴, ¹Faculty of Medicine, Memorial University of Newfoundland, St John's, NF, Canada, ²Health Access and Outcomes, QuintilesIMS, Kanata, ON, Canada, ³Inflammation & Immunology Global Outcomes & Evidence,, Pfizer, Inflammation & Immunology Global Outcomes & Evidence, Collegeville, PA, ⁴Inflammation & Immunology Global Medical Affairs, Pfizer, Collegeville, PA
Background/Purpose: Etanercept (ETN) was the first biologic approved for use in the treatment of patients with polyarticular-course juvenile idiopathic arthritis (JIA),1 and is now indicated…